Promoter shareholding increased significantly by 16.32% YoY and QoQ, indicating strong insider confidence in Cohance Lifesciences.

Institutional and public shareholding declined, with institutions down 6.23% YoY, suggesting potential caution among smart money despite promoter optimism.

In a sector where institutional changes are neutral, the divergence in promoter activity positions Cohance as a contrarian favorite amidst a generally stable sector.